James Barnaby Trager
9Patents
4h-index
15Co-inventors
46Inventor score
Filing activity: Sep 5, 2014 → May 10, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11253547B2 | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy | Chemistry; Metallurgy | 6 | Active |
| US11365236B2 | Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy | Chemistry; Metallurgy | 6 | Active |
| US11154575B2 | Cancer immunotherapy using CD19-directed chimeric antigen receptors | Chemistry; Metallurgy | 4 | Active |
| US11141436B2 | Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy | Chemistry; Metallurgy | 4 | Active |
| US12012458B2 | Genetically modified natural killer cells for CD70-directed cancer immunotherapy | Chemistry; Metallurgy | 1 | Active |
| US12398187B2 | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy | Human Necessities | 0 | Active |
| US11970743B2 | Gene expression markers for predicting overall survival in subjects treated with sipuleucel-T | Chemistry; Metallurgy | 0 | Active |
| US12351617B2 | Immune cells comprising truncated NKG2D chimeric receptors | Chemistry; Metallurgy | 0 | Active |
| US10261091B2 | Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.